Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus ARICEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus ARICEPT.
ADLARITY vs ARICEPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor